| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Ruxolitinib |
| Brand | Jakavi® |
| Indication | For the treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. |
| Assessment Process | |
| Rapid review commissioned | 01/08/2012 |
| Rapid review completed | 10/08/2012 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 20/12/2012 |
| NCPE assessment completed | 09/07/2013 |
| NCPE assessment outcome | Reimbursement not Recommended |
The NCPE do not consider ruxolitinib to be a cost effective treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.
The HSE has approved reimbursement following confidential price negotiations July 2015.